Histogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace. Its product candidate includes NeoCart, which is in Phase III clinical trials, intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. The company has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.
http://www.priceseries.com/trade/HSGX-Histogenics-Corporation-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2018060120180619.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments